Sumitomo Mitsui Trust Holdings Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 14.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,968,143 shares of the biopharmaceutical company’s stock after selling 516,559 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.24% of Gilead Sciences worth $203,644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Gilead Sciences in the 4th quarter valued at $1,301,624,000. The Manufacturers Life Insurance Company boosted its position in shares of Gilead Sciences by 78.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock valued at $618,268,000 after purchasing an additional 3,362,505 shares during the period. Vanguard Group Inc. grew its stake in Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after buying an additional 2,910,147 shares during the last quarter. Wellington Management Group LLP lifted its stake in Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after buying an additional 2,350,550 shares during the last quarter. Finally, Swedbank AB acquired a new stake in shares of Gilead Sciences in the first quarter valued at approximately $134,489,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Price Performance
Gilead Sciences stock traded down $0.56 during mid-day trading on Friday, hitting $73.78. 5,148,098 shares of the company were exchanged, compared to its average volume of 7,321,358. The business’s 50 day simple moving average is $70.80 and its two-hundred day simple moving average is $70.26. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The company has a market capitalization of $91.92 billion, a P/E ratio of 204.94, a PEG ratio of 3.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s dividend payout ratio is presently 855.56%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- The Significance of Brokerage Rankings in Stock Selection
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Euro STOXX 50 Index?
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.